Trial Profile
An Open-Label, Randomized, Multicenter Study to Evaluate the Use of Zoledronic Acid in the Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Letrozole as Adjuvant Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Bone resorption; Early breast cancer; Osteoporosis
- Focus Therapeutic Use
- Acronyms Z-FAST
- Sponsors Novartis; Novartis Pharmaceuticals
- 25 May 2010 New trial record